87248-13-3|Vapiprost hydrochloride|4-Heptenoic acid, 7-(5-((1,1'-biphenyl)-4-ylmethoxy)-3-hydroxy-2-(1-piperidinyl)cyclopentyl)-, hydrochloride, (1R-(1alpha(Z),2beta,3beta,5alpha))-|-范德生物科技公司

Vapiprost hydrochloride

NMR下载 COA and HPLC MSDS下载
names：
4-Heptenoic acid, 7-(5-((1,1'-biphenyl)-4-ylmethoxy)-3-hydroxy-2-(1-piperidinyl)cyclopentyl)-, hydrochloride, (1R-(1alpha(Z),2beta,3beta,5alpha))-
CAS号：
87248-13-3
MDL Number：
MF(分子式)： C30H40ClNO4 MW(分子量)： 514.103
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	4-Heptenoic acid, 7-(5-((1,1'-biphenyl)-4-ylmethoxy)-3-hydroxy-2-(1-piperidinyl)cyclopentyl)-, hydrochloride, (1R-(1alpha(Z),2beta,3beta,5alpha))-
英文别名	Vapiprost hydrochloride; GR 32191B; GR-32191B; GR32191B.
CAS号	87248-13-3
Inchi	InChI=1S/C30H39NO4.ClH/c32-27-21-28(35-22-23-15-17-25(18-16-23)24-11-5-3-6-12-24)26(13-7-1-2-8-14-29(33)34)30(27)31-19-9-4-10-20-31;/h1-3,5-6,11-12,15-18,26-28,30,32H,4,7-10,13-14,19-22H2,(H,33,34);1H/b2-1-;/t26-,27-,28-,30+;/m0./s1
InchiKey	ZYOBZRTZRQKKNC-UGNABIHOSA-N
分子式 Formula	C30H40ClNO4
分子量 Molecular Weight	514.103
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Vapiprost hydrochloride(CAS:87248-13-3):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Vapiprost hydrochloride is a biochemicla.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Cracowski JL, Stanke-Labesque F, Devillier P, Chavanon O, Hunt M, Souvignet C, Bessard G. Human internal mammary artery contraction by isoprostaglandin f(2alpha) type-III [8-iso-prostaglandin F(2alpha)]. Eur J Pharmacol. 2000 May 26;397(1):161-8. PubMed PMID: 10844110.

[2]Barchasz E, Naline E, Molimard M, Moreau J, Georges O, Emonds-Alt X, Advenier C. Interleukin-1beta-induced hyperresponsiveness to [Sar9,Met(O2)11]substance P in isolated human bronchi. Eur J Pharmacol. 1999 Aug 20;379(1):87-95. PubMed PMID: 10499376.

[3] Horie S, Yamada M, Satoh M, Noritake S, Hiraishi S, Kizaki K, Kurusu O, Nakahara T, Ishii H, Kazama M. The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets. Biol Pharm Bull. 1997 Jun;20(6):625-31. PubMed PMID: 9212979.

[4] Molimard M, Martin CA, Naline E, Hirsch A, Advenier C. Role of thromboxane A2 in bradykinin-induced human isolated small bronchi contraction. Eur J Pharmacol. 1995 May 4;278(1):49-54. PubMed PMID: 7545124.

[5] Ogletree ML, Allen GT. Interspecies differences in thromboxane receptors: studies with thromboxane receptor antagonists in rat and guinea pig smooth muscles. J Pharmacol Exp Ther. 1992 Feb;260(2):789-94. PubMed PMID: 1531361.

6: Takahara K, Murray R, FitzGerald GA, Fitzgerald DJ. The response to thromboxane A2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems. J Biol Chem. 1990 Apr 25;265(12):6836-44. PubMed PMID: 2139029.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开